CN106420970A - Pharmaceutical composition for curing premature ovarian failure - Google Patents
Pharmaceutical composition for curing premature ovarian failure Download PDFInfo
- Publication number
- CN106420970A CN106420970A CN201611057545.1A CN201611057545A CN106420970A CN 106420970 A CN106420970 A CN 106420970A CN 201611057545 A CN201611057545 A CN 201611057545A CN 106420970 A CN106420970 A CN 106420970A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- ovarian failure
- premature ovarian
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a pharmaceutical composition and application of the pharmaceutical composition, particularly relates to a pharmaceutical composition for curing premature ovarian failure and application thereof, and belongs to the field of medical technology. The active pharmaceutical ingredients of the pharmaceutical composition comprise the traditional Chinese medicines of herba cistanche, tortoise shell, mulberry, radix paeoniae alba, radix salviae miltiorrhizae, safflower carthamus, ossa draconis and tuber fleeceflower stem. The pharmaceutical composition is precise in component and reasonable in compatibility of medicine, the active pharmaceutical ingredients of the pharmaceutical composition mutually work together to take the effects of warming yang, invigorating kidney, activating blood to promote menstruation and tranquilizing by nourishing the heart, the pharmaceutical composition has a remarkable effect on curing premature ovarian failure, particularly the kidney yang deficiency type premature ovarian failure, and has a broad medical application prospect.
Description
Technical field
The present invention relates to a kind of medical composition and its use, more particularly to a kind of medicine group for treating premature ovarian failure
Compound and application thereof, belongs to pharmaceutical technology field.
Background technology
Ovary is the genitals of jenny, and its function is to produce ovum and steroid hormone.Modern female is more next
More focus on the maintenance of ovary, because modern study finds that ovary is healthy and in good condition, skin of face can be made moist,
White touched with red, maintain toughness and elasticity；Promote reproduction and body health, adjust and secrete ovary maintaining and female sex hormone is secreted, carry
High two life quality；Chest is plentiful, consolidation, mellow and full.30 years old later women can gradually step into ovarian function under normal circumstances
Phase of decline, but the change with current living environment, the quickening of work rhythm, discovery of multiple unidentified illness etc., ovary morning
The risk factor of morbidity of declining is greatly increased, and is caused its sickness rate in the trend for rising year by year, has been had a strong impact on the life of Contemporary Female
Grow Health and Living quality.
Premature ovarian failure belongs to the categories such as motherland's medical science " amenorrhea ", " blood depletion ", " blood every ".Pathogenesis is deficiency of kidney-essence, asthenia of qi and blood
Weak, feelings will pent-up.Ancients think, kidney storing essence and main reproduction.Essential substance for reproduction Tibetan in kidney, also belong to the category of kidney yin, the cloudy essence of blood
Between three, mutual dependence for existence is unified each other, is that material base is established in the cycle differentiation of menstruation, and therefore Chinese traditional treatment is many mends from YIN nourishing
Kidney is started with, and Chinese medicine has the integrally-regulated effect of multisystem, too many levels, Mutiple Targets, can significantly adjust overall work(
Can, reactivity of the ovary to promoting sexual gland hormone is improved, and then is recovered and improve ovarian function, swash for female than simple application Western medicine
The intervention that plain level reduces has a clear superiority, and can avoid the untoward reaction that gonadal hormone brings.Therefore, for premature ovarian failure
Treatment, the exploitation of traditional Chinese medical science natural drug and with having bigger advantage and prospect.
Content of the invention
In order to solve prior art deficiency, the invention provides a kind of specific aim is higher, cheap, it is difficult after healing multiple
Send out, the less Chinese medicine composition of side effect, its active constituents of medicine is made up of following traditional Chinese medicines：Herba Cistanches, Carapax Et Plastrum Testudiniss, Fructus Mori, white
Chinese herbaceous peony, Radix Salviae Miltiorrhizae, Flos Carthami, Os Draconis, Caulis Polygoni Multiflori.Chinese medicine composition of the present invention is particularly kidney-yang deficiency for treatment premature ovarian failure of women
Premature ovarian failure curative effect is extremely notable, with wide medical application prospect.
The primary efficacy of each component is as follows further：
Herba Cistanches：【Nature and flavor】Sweet, salty, temperature.【Return through】Return kidney, large intestine channel.【Indication】Kidney-replenishing, benefiting essence-blood, intestine moistening
Relieving constipation.For sexual impotence, infertile, soreness of the waist and knees, muscles and bones is powerless, dry constipation of intestines.
Carapax Et Plastrum Testudiniss：【Nature and flavor】Salty, sweet, it is slightly cold.【Return through】Return liver, kidney, heart channel.【Indication】Nourishing YIN for suppressing the hyperactive YANG, kidney tonifying bone strengthening,
Blood-nourishing reinforcing the heart.For deficiency of YIN hectic fever, hectic fever due to YIN-deficiency night sweat, have a dizzy spell, stirring-up of pathogenic wind in the interior resulting from deficiency, muscles and bones impotence, have a guilty conscience forgetful.
Fructus Mori：【Nature and flavor】Sweet；Acid；Cold in nature.【Return through】Liver；Kidney channel.【Indication】Nourishing YIN and benefiting blood；Promote the production of body fluid；Intestine moistening.Main
The having a dizzy spell of deficiency of the liver and kindey and blood deficiency damage of essence；Soreness of waist tinnitus；Early whitening of beard and hair；Insomnia and dreamful sleep；Injury thirst；Quench one's thirst；Dryness of the intestine is just
Secret.
The Radix Paeoniae Alba：【Nature and flavor】Bitter, sour, it is slightly cold.【Return through】Return liver, spleen channel.【Indication】Smooth liver and relieve pain, nourishing blood for regulating menstruation, hold back
Cloudy hidroschesis.For dizziness of having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat.
Radix Salviae Miltiorrhizae：【Nature and flavor】Hardship, is slightly cold.【Return through】GUIXIN, Liver Channel.【Indication】Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire and remove
Tired.For menoxenia, closed dysmenorrhea, abdominal mass is gathered, chest and abdomen shouting pain, hot numbness pain, sore swell and ache curative, dysphoria and insomnia；Liver splenomegaly
Greatly, angina pectoriss.
Flos Carthami：【Nature and flavor】Pungent, temperature.【Return through】GUIXIN, Liver Channel.【Indication】Promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.For warp
Close, dysmenorrhea, lochia, abdominal mass mass in the abdomen, injury from falling down, sore swell and ache curative.
Os Draconis：【Nature and flavor】Sweet, puckery, put down.【Indication】Calmness, puckery essence of arrest sweating, promoting tissue regeneration and ulcer healing.For neurasthenia, the heart
Throb with fear, insomnia, dreaminess, spontaneous perspiration, night sweat, seminal emission, the enuresis, metrorrhagia, leukorrhagia；Skin infection bursts for a long time and does not holds back is controlled in external.(being decocted first)
Caulis Polygoni Multiflori：【Nature and flavor】Sweet；Slight bitter；Mild-natured.【Return through】The heart；Liver Channel.【Indication】Tranquilizing by nourishing the heart；Wind-dispelling；Dredging collateral.
Main insomnia；Dreaminess；Blood deficiency general pain；Numbness of the skin；Rheumatic arthralgia；Rubella itch.
One of the object of the invention is to provide a kind of pharmaceutical composition for treating premature ovarian failure.Medicine group of the present invention
The rigorous prescription of compound, reasonable compatibility, full side interacts, and plays temperature male wind-supplying kidney altogether, promoting blood circulation to restore menstrual flow, and the special effect of tranquilizing by nourishing the heart is being controlled
Unexpected treatment or preventive effect is achieved in terms for the treatment of premature ovarian failure.Based on this, the preferred pharmaceutical composition of the present invention
The weight proportion of each component is：Herba Cistanches 12-20 weight portion, Carapax Et Plastrum Testudiniss 5-15 weight portion, Fructus Mori 12-20 weight portion, Radix Paeoniae Alba 4-8
Weight portion, Radix Salviae Miltiorrhizae 6-10 weight portion, Flos Carthami 10-14 weight portion, Os Draconis 10-14 weight portion, Caulis Polygoni Multiflori 6-10 weight portion.Most preferably
, the parts by weight of each Chinese medicine of described pharmaceutical composition are：16 weight portion of Herba Cistanches, 10 weight portion of Carapax Et Plastrum Testudiniss, 16 weight of Fructus Mori
Amount part, 6 weight portion of the Radix Paeoniae Alba, 8 weight portion of Radix Salviae Miltiorrhizae, 12 weight portion of Flos Carthami, 12 weight portion of Os Draconis, 8 weight portion of Caulis Polygoni Multiflori.
Present invention also offers the preparation method of pharmaceutical composition active component, specifically comprises the steps of：Take Carapax Et Plastrum Testudiniss and
Os Draconis, add up 5-10 times of weight of water, first decoct 1.5 hours, place into remaining medical material, soak 30-60 minute, decoct 1-3
Secondary, each 2-3 hour, filtration, merging filtrate, the extractum of filtrate reduced in volume to relative density 1.10-1.15, the relative density
It is the testing result at 65 DEG C, it is 75% (v/v), to stand 24 hours to alcohol content to add ethanol, takes supernatant, reclaims ethanol
To concentrating, dry, obtain final product.
The pharmaceutical composition for the treatment of premature ovarian failure of the present invention, preferably oral administration, the oral system that such as commonly uses
Agent such as tablet, capsule or suspensoid；Preferably, the oral formulations are tablet；It is further preferred that the tablet is slow release
Piece.
The two of the object of the invention are the open pharmaceutical preparation containing aforementioned pharmaceutical compositions.Inventor is made by test
Standby become more stable oral formulations, such as tablet, capsule, suspensoid.Wherein tablet contains two or more following adjuvants：Form sediment
Powder, dextrin, low-substituted hydroxypropyl cellulose, magnesium stearate, Microcrystalline Cellulose, hydroxypropyl cellulose, starch slurry Lactose, manna
Alcohol, micropowder silica gel, Croscarmellose Sodium and crospolyvinylpyrrolidone；The capsule contains two or more as follows
Adjuvant：Amylum pregelatinisatum, Lactose, low-substituted hydroxypropyl cellulose, Microcrystalline Cellulose and micropowder silica gel；The suspensoid contains two
Following adjuvant more than kind：Zinc sulfate, camphor spirit, sodium carboxymethyl cellulose, glycerol, Carbomer；The slow releasing tablet or slow releasing capsule
In contain two or more following adjuvants：Microcrystalline Cellulose, Lactose, methylcellulose (MC), ethyl cellulose (EC), ethoxy fibre
Dimension plain (HEC), hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), pregel form sediment
Powder.
Based on the test examples of the present invention, the present invention is also claimed aforementioned pharmaceutical compositions and controls preparing premature ovarian failure
Treat the purposes in medicine.Oral administration is preferably during aforementioned pharmaceutical compositions administration.As shown in the embodiment of the present invention 6, can see
Go out：Pharmaceutical composition of the present invention has positive therapeutical effect.It is embodied in：I group is tested respectively compared with II-IV group of test
Work well in terms of with significant difference, clinical symptoms, this shows that pharmaceutical composition of the present invention can improve ovary to promoting
The reactivity of sex gland hormoneies, recovers and improves ovarian function, has good therapeutic effect to kidney yang deficiency syndrome premature ovarian failure.
Specific embodiment
The present invention is further illustrated below by way of specific embodiment, but those skilled in the art should know the tool of the present invention
Body embodiment simultaneously limits the present invention, and any equivalent done on the basis of the present invention each falls within this never in any form
The protection domain of invention.
Prepared by 1 medicinal composition tablets of embodiment
Preparation technology：
1) preparation of active component：In prescription, the parts by weight of each Chinese medicine are：16 weight portion of Herba Cistanches, 10 weight of Carapax Et Plastrum Testudiniss
Part, 16 weight portion of Fructus Mori, 6 weight portion of the Radix Paeoniae Alba, 8 weight portion of Radix Salviae Miltiorrhizae, 12 weight portion of Flos Carthami, 12 weight portion of Os Draconis, 8 weight of Caulis Polygoni Multiflori
Amount part.
Carapax Et Plastrum Testudiniss and Os Draconis are taken, 5-10 times of weight of water is added up, first decoct 1.5 hours, remaining medical material is placed into, soak
30-60 minute, decoct 1-3 time, each 2-3 hour, filtration, merging filtrate, filtrate reduced in volume is to relative density 1.10-1.15
Extractum, the relative density is the testing result at 65 DEG C, add ethanol to alcohol content be 75% (v/v), stand 24 hours,
Supernatant is taken, and ethanol is reclaimed to concentrating, is dry, obtain final product.
2) active component of recipe quantity and above-mentioned adjuvant mix homogeneously are weighed.60% ethanol of Sq is separately taken, is incorporated in
In mixed-powder, soft material processed after mix homogeneously, pelletized by 16 mesh sieves, less than 60 DEG C dry.40 mesh sieves are used after the completion of after drying
Granulate is carried out, the fine powder in dry granular is sifted out, mix with the magnesium stearate that sieves, be then mixed evenly with dry particl again, tabletting, i.e.,
?.
Prepared by 2 medicinal composition tablets of embodiment
Preparation technology：
1) preparation of active component：
In prescription, the parts by weight of each Chinese medicine are：12 weight portion of Herba Cistanches, 5 weight portion of Carapax Et Plastrum Testudiniss, 12 weight portion of Fructus Mori, white
4 weight portion of Chinese herbaceous peony, 6 weight portion of Radix Salviae Miltiorrhizae, 10 weight portion of Flos Carthami, 10 weight portion of Os Draconis, 6 weight portion of Caulis Polygoni Multiflori.
Carapax Et Plastrum Testudiniss and Os Draconis are taken, 5-10 times of weight of water is added up, first decoct 1.5 hours, remaining medical material is placed into, soak
30-60 minute, decoct 1-3 time, each 2-3 hour, filtration, merging filtrate, filtrate reduced in volume is to relative density 1.10-1.15
Extractum, the relative density is the testing result at 65 DEG C, add ethanol to alcohol content be 75% (v/v), stand 24 hours,
Supernatant is taken, and ethanol is reclaimed to concentrating, is dry, obtain final product.
2) active component of recipe quantity and above-mentioned adjuvant mix homogeneously are weighed.8% starch slurry solution of Sq is separately taken, plus
Enter in mixed-powder, soft material processed after mix homogeneously, pelletized by 16 mesh sieves, less than 60 DEG C dry.40 mesh are used after the completion of after drying
Sieve carries out granulate, sifts out the fine powder in dry granular, mixes with the magnesium stearate that sieves, is then mixed evenly with dry particl again, tabletting,
Obtain final product.
Prepared by 3 medicinal composition tablets of embodiment
Preparation technology：
1) preparation of active component：
In prescription, the parts by weight of each Chinese medicine are：20 weight portion of Herba Cistanches, 15 weight portion of Carapax Et Plastrum Testudiniss, 20 weight portion of Fructus Mori,
8 weight portion of the Radix Paeoniae Alba, 10 weight portion of Radix Salviae Miltiorrhizae, 14 weight portion of Flos Carthami, 14 weight portion of Os Draconis, 10 weight portion of Caulis Polygoni Multiflori.
Carapax Et Plastrum Testudiniss and Os Draconis are taken, 5-10 times of weight of water is added up, first decoct 1.5 hours, remaining medical material is placed into, soak
30-60 minute, decoct 1-3 time, each 2-3 hour, filtration, merging filtrate, filtrate reduced in volume is to relative density 1.10-1.15
Extractum, the relative density is the testing result at 65 DEG C, add ethanol to alcohol content be 75% (v/v), stand 24 hours,
Supernatant is taken, and ethanol is reclaimed to concentrating, is dry, obtain final product.
2) active component of recipe quantity and above-mentioned adjuvant mix homogeneously are weighed.60% ethanol of Sq is separately taken, is incorporated in
In mixed-powder, soft material processed after mix homogeneously, pelletized by 16 mesh sieves, less than 60 DEG C dry.40 mesh sieves are used after the completion of after drying
Granulate is carried out, the fine powder in dry granular is sifted out, mix with the magnesium stearate that sieves, be then mixed evenly with dry particl again, tabletting, i.e.,
?.
Prepared by 4 medicinal composition tablets of embodiment
Preparation technology：
1) preparation of active component：
In prescription, the parts by weight of each Chinese medicine are：10 weight portion of Herba Cistanches, 10 weight portion of Carapax Et Plastrum Testudiniss, 25 weight portion of Fructus Mori,
6 weight portion of the Radix Paeoniae Alba, 8 weight portion of Radix Salviae Miltiorrhizae, 6 weight portion of Flos Carthami, 12 weight portion of Os Draconis, 8 weight portion of Caulis Polygoni Multiflori.
The other the same as in Example 1.
Prepared by 5 medicinal composition tablets of embodiment
Preparation technology：
1) preparation of active component：
In prescription, the parts by weight of each Chinese medicine are：16 weight portion of Semen Cuscutae, 10 weight portion of Carapax Et Plastrum Testudiniss, 16 weight portion of Fructus Mori,
6 weight portion of the Radix Paeoniae Alba, 8 weight portion of Radix Salviae Miltiorrhizae, 12 weight portion of Flos Carthami, 12 weight portion of Concha Ostreae, 8 weight portion of Caulis Polygoni Multiflori..
The other the same as in Example 1.
The clinical observation test of the pharmaceutical composition of the present invention of embodiment 6.
1. physical data：
Choosing 160 and the patient of premature ovarian failure is diagnosed as object of study in the court, and is insufficiency of kidney-YANG through Chinese medical discrimination
Type.Age 20-40 year, average (32.04 ± 5.12) year, the course of disease average (1.60 ± 0.94) year, be randomly divided into test I, II,
IIIth, IV group each 40.Four groups of ages, courses of disease etc. compare, and difference there are no significant meaning (P ＞ 0.05), with comparability.
2. case selection standard
Western medicine diagnostic criteria occurred at least 4 months in 40 years old in the past with reference to " clinical manifestation of premature ovarian failure and diagnostic criteria "
Above amenorrhea, and have 2 times or more serum follicule-stimulating hormone (FSH) (FSH)>40U/L (2 inspection intervals more than 1 month), estradiol
(E2)<73.2pmol/L.
Tcm diagnosis standard：Menopause praecox or overage also menolipsiss menophania, pale complexion, lassitude, soreness of waist cold type of pain, body
Cold, libido indifference, frequent micturition etc., pale tongue, deep-thready pulse or heavy powerless late.
3. inclusive criteria：Meet diagnostic criteria, and nearly three months not using hormone person.
4. process of the test：
Test I group：The tablet of the preparation of embodiment 1 is taken, per piece 0.20g containing crude drug amount, 4 tablets once, and 2 times a day.
Test II group：The tablet of the preparation of embodiment 4 is taken, per piece 0.20g containing crude drug amount, 4 tablets once, and 2 times a day.
Test III group：The tablet of the preparation of embodiment 5 is taken, per piece 0.20g containing crude drug amount, 4 tablets once, and 2 times a day.
Test IV group：Treated with estrogen-progestogen cyclic treatment.Estradiol Valerate Tablets 1mg/ time, 1 time/d, serve on 21d, medication
16d adds medroxyprogestetone acetate piece, 3 times/d, 4mg/ time, serve on 5d, and menstrual onset continues to take 3 cycles on the 5th day.
It is to observe curative effect 1 course for the treatment of, after 1 course for the treatment of that four groups are 3 menstrual cycle for the treatment of.
5. the standard of curative effect evaluation：
Recovery from illness：Clinical symptom disappearance, Endocrinological inspection serum hormone is normal, menstrual onset and continuous more than 3 times normal row
Warp；
Effectively：Symptom substantially mitigates, and menstruation recovery is risen, but the cycle is abnormal, Endocrinological inspection serum hormone take a turn for the better or
It is close to normal；
Invalid：Symptom and sign and Endocrinological inspection are not improved.
Total effective rate=(recovery from illness number of cases+effective number of cases)/total number of cases × 100%.
6. statistical method
With statistics software SPSS20.0, statistical analysis are carried out to data, enumeration data adopts x2Inspection；Measurement data
With mean ± standard deviationRepresent, carry out t inspection；Between P ＜ 0.05 represents two groups, diversity is notable.
7. therapeutic outcome
1) the concrete therapeutic outcome of test each group is as shown in table 1.
Table 1：Four groups for the treatment of clinical effectiveness
| Group | n | Recovery from illness | Effectively | Invalid | Total effective rate |
| Test I group | 40 | 22 | 16 | 2 | 95%*◎& |
| Test II group | 40 | 10 | 19 | 11 | 72.5% |
| Test III group | 40 | 9 | 21 | 10 | 75% |
| Test IV group | 40 | 12 | 19 | 9 | 77.5% |
Note：Test I group with test II group compare, * P ＜ 0.05；III group is compared with test,◎P ＜ 0.05；With test IV group
Relatively,&P ＜ 0.05.
Compare from table 1 as can be seen that 22 people that fully recover I group, total effective rate 95% is tested, other test group are superior to, and
Significant difference (P ＜ 0.05), with statistical significance, though curative effect is variant between other each groups, does not have statistical significance (P
＞ 0.05), specifically, the clinical effectiveness of II, III group of test shows, arbitrarily changes prescription proportioning, it is impossible to reach the present invention's
Therapeutic effect.
Meanwhile, allergic phenomena and untoward reaction is not found using I group of the test of the Chinese medicine composition tablet of the present invention,
Subsequently to I group of recovery from illness patient of test continuous Follow-up observation half a year, the phenomenon of case recurrence is not found.
To sum up, the invention provides a kind of Chinese medicine composition and preparation method thereof, the Chinese medicine composition prescription is rigorous, compatibility
Rationally, full side interacts, and plays temperature male wind-supplying kidney altogether, promoting blood circulation to restore menstrual flow, and the special effect of tranquilizing by nourishing the heart, for treatment premature ovarian failure of women spy
It is not that kidney-yang deficiency premature ovarian failure curative effect is extremely notable,.In addition, the method for preparing Chinese medicine composition that the present invention is provided, profit
With the effective ingredient of modern preparation technology rapid extraction said composition, the method is simple, is suitable for high-volume and promotes production.
The preferred embodiment of the present invention described in detail above, but, the present invention is not limited in above-mentioned embodiment
Detail, in the range of the technology design of the present invention, multiple simple variant can be carried out to technical scheme, this
A little simple variant belong to protection scope of the present invention.
Additionally, combination in any can also be carried out between a variety of embodiments of the present invention, as long as which is without prejudice to this
The thought of invention, which should equally be considered as content disclosed in this invention.
Claims (7)
1. a kind of pharmaceutical composition for treating premature ovarian failure, it is characterised in that its active constituents of medicine is made up of following traditional Chinese medicines：Meat
Herba Cistanchess, Carapax Et Plastrum Testudiniss, Fructus Mori, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Flos Carthami, Os Draconis, Caulis Polygoni Multiflori.
2. pharmaceutical composition as claimed in claim 1, it is characterised in that the parts by weight of each Chinese medicine in described pharmaceutical composition
For：Herba Cistanches 12-20 weight portion, Carapax Et Plastrum Testudiniss 5-15 weight portion, Fructus Mori 12-20 weight portion, Radix Paeoniae Alba 4-8 weight portion, Radix Salviae Miltiorrhizae 6-10
Weight portion, Flos Carthami 10-14 weight portion, Os Draconis 10-14 weight portion, Caulis Polygoni Multiflori 6-10 weight portion.
3. pharmaceutical composition as claimed in claim 1, it is characterised in that the parts by weight of each Chinese medicine of described pharmaceutical composition
For：16 weight portion of Herba Cistanches, 10 weight portion of Carapax Et Plastrum Testudiniss, 16 weight portion of Fructus Mori, 6 weight portion of the Radix Paeoniae Alba, 8 weight portion of Radix Salviae Miltiorrhizae, Flos Carthami 12
Weight portion, 12 weight portion of Os Draconis, 8 weight portion of Caulis Polygoni Multiflori.
4. the pharmaceutical composition as described in claim 1-3 is arbitrary, it is characterised in that described pharmaceutical composition be.
5. pharmaceutical composition as claimed in claim 4, it is characterised in that the oral formulations can be tablet, capsule, mixed
Suspension, preferably tablet.
6. the arbitrary described pharmaceutical composition of claim 1-3 treats the purposes in the medicine of premature ovarian failure in preparation.
7. the arbitrary described pharmaceutical composition of claim 1-3 treats the use in the medicine of kidney-yang deficiency premature ovarian failure in preparation
On the way.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610137795X | 2016-03-10 | ||
| CN201610137795.XA CN105616561A (en) | 2016-03-10 | 2016-03-10 | Medicine composition for treating premature ovarian failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420970A true CN106420970A (en) | 2017-02-22 |
Family
ID=56032176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610137795.XA Pending CN105616561A (en) | 2016-03-10 | 2016-03-10 | Medicine composition for treating premature ovarian failure |
| CN201611057545.1A Withdrawn CN106420970A (en) | 2016-03-10 | 2016-11-26 | Pharmaceutical composition for curing premature ovarian failure |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610137795.XA Pending CN105616561A (en) | 2016-03-10 | 2016-03-10 | Medicine composition for treating premature ovarian failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105616561A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114712447A (en) * | 2022-03-07 | 2022-07-08 | 四川汇智启创科技服务有限公司 | Pharmaceutical composition for preventing and treating premature ovarian failure and improving osteoporosis and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112089822A (en) * | 2020-10-26 | 2020-12-18 | 北京沃德中医药研究院 | Traditional Chinese medicine preparation for conditioning premature ovarian failure of women and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623087A (en) * | 2013-11-19 | 2014-03-12 | 靖江市明星水蛭养殖专业合作社 | Traditional Chinese medicine formula for treating irregular menstruation and preparation method of traditional Chinese medicine formula |
-
2016
- 2016-03-10 CN CN201610137795.XA patent/CN105616561A/en active Pending
- 2016-11-26 CN CN201611057545.1A patent/CN106420970A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623087A (en) * | 2013-11-19 | 2014-03-12 | 靖江市明星水蛭养殖专业合作社 | Traditional Chinese medicine formula for treating irregular menstruation and preparation method of traditional Chinese medicine formula |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114712447A (en) * | 2022-03-07 | 2022-07-08 | 四川汇智启创科技服务有限公司 | Pharmaceutical composition for preventing and treating premature ovarian failure and improving osteoporosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105616561A (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN102657821A (en) | Drug for treating ovarian cyst | |
| CN106420970A (en) | Pharmaceutical composition for curing premature ovarian failure | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN110201122B (en) | Traditional Chinese medicine composition for treating irregular menstruation and preparation method and application thereof | |
| CN104189461B (en) | One treats osteoporotic Chinese medicine compound and preparation method thereof | |
| CN102670885B (en) | Medicine for treating cough and asthma and preparation method thereof | |
| CN103041112B (en) | Traditional Chinese medicine for treating simple obesity fatty liver | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN102198202A (en) | Pills for treating gout | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN101837056B (en) | Foot-bath effervescent tablet for improving blood stasis-type thoracic obstruction caused by qi deficiency | |
| CN105213905A (en) | A kind of Chinese medicine composition and application thereof preventing and treating postmenopausal osteoporosis | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104258037A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
| CN104547700B (en) | A kind of Chinese medicine composition for the treatment of preceeded menorrhea | |
| CN102793874B (en) | Traditional Chinese medicine preparation capable of reducing hematuria and proteinuria of patient with lupus nephritis | |
| CN107441313B (en) | Traditional Chinese medicine composition and medicine for treating ovarian reserve function decline and preparation method thereof | |
| CN104623415A (en) | Pharmaceutical composition for treating nephropathy and application thereof | |
| CN104825756A (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
| CN104306905A (en) | Traditional Chinese medicine combination for treating hypertension and preparing method of traditional Chinese medicine combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |